Valuation: DMS

Market Cap 3.12Cr 3.57Cr 2.88Cr 2.66Cr 5.01Cr 344.12Cr 5.12Cr 34Cr 14Cr 168.54Cr 13Cr 13Cr 580.19Cr P/E 2026 *
40.2x
P/E 2027 * 12.1x
Enterprise Value 4.66Cr 5.34Cr 4.3Cr 3.97Cr 7.48Cr 513.83Cr 7.64Cr 51Cr 20Cr 251.65Cr 20Cr 20Cr 866.31Cr EV / Sales 2026 *
0.82x
EV / Sales 2027 * 0.6x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.57Cr
-1.21%+1.26%-13.71%-19.02% 1.34TCr
-6.37%-15.89%+41.04%-11.18% 386.25Cr
-0.76%-0.17%+71.16%+109.12% 124.03Cr
-4.45%-0.26%-35.24%-60.78% 118.4Cr
-4.35%-2.94%-40.50%-47.30% 109.43Cr
-3.75%+6.82%-42.81% - 94Cr
-8.55%-20.41%+61.00%+89.90% 49Cr
+5.01%+12.02%+47.47% - 34Cr
+1.55%+1.73%-56.66%+239.01% 27Cr
Average -2.29%-0.12%+3.53%+42.82% 252.94Cr
Weighted average by Cap. -2.52%-0.29%-1.40%-8.29%

Financials

2026 *2027 *
Net sales 5.68Cr 6.5Cr 5.24Cr 4.83Cr 9.11Cr 625.92Cr 9.31Cr 63Cr 25Cr 306.55Cr 24Cr 24Cr 1.06TCr 6.59Cr 7.54Cr 6.08Cr 5.61Cr 11Cr 726.2Cr 11Cr 73Cr 29Cr 355.66Cr 28Cr 28Cr 1.22TCr
Net income 8L 9L 7L 7L 12.83L 8.82Cr 13.11L 88.24L 34.71L 4.32Cr 34.38L 33.62L 15Cr 26L 29.75L 23.99L 22.11L 41.68L 29Cr 42.61L 2.87Cr 1.13Cr 14Cr 1.12Cr 1.09Cr 48Cr
Net Debt 1.54Cr 1.76Cr 1.42Cr 1.31Cr 2.47Cr 169.7Cr 2.52Cr 17Cr 6.68Cr 83Cr 6.62Cr 6.47Cr 286.12Cr 80L 91.54L 73.82L 68.05L 1.28Cr 88Cr 1.31Cr 8.82Cr 3.47Cr 43Cr 3.44Cr 3.36Cr 148.63Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-